Anaptysbio (ANAB) Capital Expenditures (2016 - 2026)
Anaptysbio's (ANAB) quarterly Capital Expenditures came in at $17000.0 in Q1 2026, up 54.55% YoY from $11000.0 in Q1 2025, and down 80.46% on a QoQ basis from $87000.0 in Q4 2025.
Anaptysbio (ANAB) Capital Expenditures (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Capital Expenditures data on file, last reported at $17000.0 in Q1 2026.
- Quarterly Capital Expenditures rose 54.55% year-over-year to $17000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93000.0 (up 1133.33% YoY) and the FY2025 annual result came in at $87000.0, up 1142.86% from the prior year.
- Capital Expenditures slipped to $17000.0 in Q1 2026, from $87000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $280000.0 in Q4 2023 to a low of -$74000.0 in Q3 2025.
- A 5-year average of $63058.8 and a median of $33000.0 in 2024 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2024 — Capital Expenditures tumbled 134.57% — and 2025, when it jumped 2800.0%.
- Tracing ANAB's Capital Expenditures over 5 years: stood at $126000.0 in 2022, then soared by 122.22% to $280000.0 in 2023, then tumbled by 98.93% to $3000.0 in 2024, then jumped by 2800.0% to $87000.0 in 2025, then slumped by 80.46% to $17000.0 in 2026.
- The last three Capital Expenditures figures came in at $17000.0 (Q1 2026), $87000.0 (Q4 2025), and -$74000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | 17,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17,000.00 |
| Mar 31, 2026 | 17,000.00 |
| Dec 31, 2025 | 87,000.00 |
| Dec 31, 2025 | 87,000.00 |
| Sep 30, 2025 | -74,000.00 |
| Sep 30, 2025 | -74,000.00 |
| Jun 30, 2025 | 63,000.00 |
| Jun 30, 2025 | 63,000.00 |
| Mar 31, 2025 | 11,000.00 |
| Mar 31, 2025 | 11,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | -56,000.00 |
| Sep 30, 2024 | -56,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Dec 31, 2023 | 280,000.00 |
| Dec 31, 2023 | 280,000.00 |